Skip to content
Relatix Bio

Relatix Bio

Radically different

  • Services
  • Knowledgebase
  • Partnerships
  • Our Approach
  • Contact
  • About
    • Vision
    • Our mission
    • Privacy Policy
    • FAQ
    • News
Posted on June 22, 2026 by admin
<![CDATA[Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.]]>
CategoriesImported News TagsClinical trial, Depression, News Approved

Post navigation

Previous PostPrevious STAT+: Another big deal, another sign biotech M&A is back
Next PostNext Breast Milk Fatty Acid Shapes Immune Development in Mice

This is the footer

Privacy Policy Proudly powered by WordPress